This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Idera Pharmaceuticals Reports Second Quarter 2012 Financial Results

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported its financial results and highlights for the second quarter ended June 30, 2012.

"During the first half of 2012, we have continued to advance the development of lead candidates in our autoimmune disease program. We anticipate that the interim data from our ongoing Phase 2 study of IMO-3100 in patients with psoriasis will be available by the end of 2012. The Phase 2 study is designed to help us validate the scientific rationale of antagonizing specific Toll-like Receptors for the treatment of autoimmune diseases. We are also on target to submit an Investigational New Drug application for IMO-8400 for the treatment of lupus as a first indication in the fourth quarter of 2012," said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer. "In addition, we continue to support our collaboration with Merck in the area of TLR agonists as vaccine adjuvants for cancer, infectious diseases and Alzheimer's disease."

Financial Results

As of June 30, 2012, cash and cash equivalents totaled $13.2 million compared to $24.6 million at December 31, 2011.

Second Quarter Results

Net loss applicable to common stockholders for the three months ended June 30, 2012, was $4.0 million, or $0.15 per diluted share, compared to a net loss applicable to common stockholders of $6.3 million, or $0.23 per diluted share, for the same period in 2011. For the six-month period, the Company's net loss applicable to common stockholders was $11.1 million, or $0.40 per diluted share, compared to a net loss applicable to common stockholders of $13.1 million, or $0.48 per diluted share, for the same period in 2011.

Research and development expenses for the three months ended June 30, 2012, totaled $3.5 million compared to $4.1 million for the same period in 2011. For the six-month period, R&D expenses totaled $7.3 million compared to $8.7 million for the same period in 2011.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs